Greenovel Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-11-2024
- Paid Up Capital ₹ 1.00 M
as on 05-11-2024
- Company Age 4 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 Cr
as on 05-11-2024
- Revenue 2881.84%
(FY 2023)
- Profit 235.97%
(FY 2023)
- Ebitda 164.70%
(FY 2023)
- Net Worth 249.95%
(FY 2023)
- Total Assets 441.03%
(FY 2023)
About Greenovel Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 Cr.
Maheshwar Suryapet and Suryapeta Vijayalaxmi serve as directors at the Company.
- CIN/LLPIN
U74999TG2020PTC144262
- Company No.
144262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Greenovel Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maheshwar Suryapet  | Director | 26-Sep-2020 | Current |
| Suryapeta Vijayalaxmi | Director | 26-Sep-2020 | Current |
Financial Performance of Greenovel Life Sciences.
Greenovel Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 2881.84% increase. The company also saw a substantial improvement in profitability, with a 235.97% increase in profit. The company's net worth Soared by an impressive increase of 249.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Greenovel Life Sciences?
Unlock access to Greenovel Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
₹10.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 1.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Jan 2024 | State Bank Of India | ₹1.00 Cr | Open |
How Many Employees Work at Greenovel Life Sciences?
Greenovel Life Sciences has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Greenovel Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Greenovel Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.